ITCI

Intra-Cellular Therapies Announces FDA Acceptance of CAPLYTA® (lumateperone) sNDAs for the Treatment of Bipolar Depression

Intra-Cellular: Substantial Unlocked Value In Caplyta Franchises

Intra-Cellular Therapies Announces Investor Webcast and Presentations on Lumateperone Programs at the Upcoming American Psychiatric Association (APA) Annual Meeting

Intra-Cellular Therapies Announces Board of Director Nominations in Advance of 2021 Annual Meeting

Intra-Cellular: Label Expansion PDUFA Up Ahead

Intra-Cellular Therapies, Inc.'s (ITCI) CEO Sharon Mates on Q4 2020 Results - Earnings Call Transcript